Immune therapy tested in study of women with triple-negative breast cancer

(Johns Hopkins Medicine) Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently difficult form of the disease to treat.